Modality
Gene Editing
MOA
FGFRi
Target
PCSK9
Pathway
NF-κB
UCGastric CaGBM
Development Pipeline
Preclinical
~Jul 2019
→ ~Oct 2020
Phase 1
~Jan 2021
→ ~Apr 2022
Phase 2
~Jul 2022
→ ~Oct 2023
Phase 3
Jan 2024
→ Sep 2031
Phase 3Current
NCT05526177
1,710 pts·UC
2024-01→2031-09·Terminated
1,710 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-09-075.4y awayPh3 Readout· UC
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2031-09-07 · 5.4y away
UC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05526177 | Phase 3 | UC | Terminated | 1710 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Talatapinarof | Samsung Biologics | Phase 1/2 | PCSK9 |